Articles

Find an Article

Filter articles

Applied Filters

Showing 261 to 270 of 277 results

The likely role of the UPC in pharma patent litigation

EU28-03-2013

The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.

Waiting to inhale: MannKind's diabetes strategy

US28-03-2013

For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.

Hub and spoke? Life sciences in Northern France

France01-02-2013

It seems an unlikely place for innovation, but Lille and its surroundings play host to a burgeoning life sciences industry. LSIPR visited to find out more.

Reaching out: BIO abroad

01-01-2012

For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs.

A new framework: challenging patents in changing times

01-01-2012Eldora Ellison and Eric Steffe

The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes.

Formal obligations: burdens on biotech patents

01-01-2012

The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important.

Is there life for medical diagnostic patents after Prometheus?

01-01-2012MaryAnne Armstrong

The Supreme Court’s much-anticipated Prometheus decision has prompted strong reactions among IP practitioners, as MaryAnne Armstrong, PhD, explains.

Life sciences in Europe: the key jurisdictions

01-05-2011

The European life sciences industry has a long history. Many of the major players trace their roots to before the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions.

Covering all the bases: An interview with BIO President Jim Greenwood

01-05-2011

BIO represents a broad constituency of biotechnology and life sciences companies. LSIPR talks to BIO president and CEO Jim Greenwood about patent reform, healthcare, court cases and plans for the future.

It’s good to litigate a patent or two

01-05-2011

Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled.

Showing 261 to 270 of 277 results

LSIPR